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Introduction
Initial paradigms of ex vivo gene therapy, based on transplantation of genetically modified cells, have given way to in vivo gene therapy where the vector is directly introduced into the recipient. In vivo gene therapy has the potential of improved efficiency and expands the scope of applications to a wider array of acquired and inherited diseases. 1 An example is cystic fibrosis (CF) where a number of viral and nonviral vectors have been introduced into the airway to correct the genetic defect in respiratory epithelial cells. Vectors based on recombinant forms of human adenoviruses (Ad) and adeno-associated viruses (AAV) have played a major role in in vivo gene therapy for CF and a number of other disorders. [1] [2] [3] [4] [5] A number of factors will contribute to the outcome of in vivo gene therapy with Ad and AAV, including the nature of the immune response to vector, transgene product and transduced cell. Genetic factors, such as the genotype (eg mutation of CF gene) and MHC haplotype, will play a role. Pre-existing immunity to the virus due to naturally acquired infections will also contribute to outcome. 6 Human Ad vectors have been created by replacing the immediate early genes E1a and E1b with a therapeutic minigene. There exist over 40 serotypes of human adenovirus, although most vectors are based on serotypes 2 and 5. 7 Administration of replication-defective Ad2 and Ad5 vectors expressing the normal CF gene into the air- way has demonstrated gene transfer and partial correction of function in preclinical and clinical models. [8] [9] [10] A number of problems attributable to immune responses have emerged. B cells and T helper cells are activated to the viral capsid proteins, which leads to the secretion of neutralizing antibody (NAB) which blocks readministration of vector. Furthermore, expressed viral genes and the transgene product are presented by MHC class I resulting in activation of cytotoxic T cells that extinguish transgene expression. 6, 11 The majority of humans have circulating antibodies against the common Ad serotypes and infected individuals develop prolonged immunity to the virus. 7 Multiple factors may contribute to the generation of Ad-specific immune responses in humans.
12 About 2-5% of respiratory infections, 10% of febrile illnesses, and 5-10% of gastrointestinal infections in children are due to adenoviral infections leading to shedding of virus for weeks and even years following infections. Lymphoid organs, such as the tonsils, are probably the site for persistent infections, where viral DNA has been detected in 25% of subjects. Acute infection with Ad leads to immunity in most cases. Military recruits administered Ad7 and Ad4 live vaccines seroconvert and are protected from the disease. Ad has been associated with fatal disseminated disease in individuals with primary immune deficiencies, indicating that cellular immune responses are important for recovery from acute infections. 12, 13 Adeno-associated virus is a human parvovirus with six distinct serotypes that is not associated with disease in primates. Wild-type AAV can infect non-dividing permissive cells and integrate as a proviral genome into a specific site in chromosome 19. Over 90% of humans demonstrate antibodies that cross-react to one or more AAV serotypes. [14] [15] [16] Replication-defective forms of AAV serotype 2 (AAV2) have been generated in which all viral open reading frames are deleted from the vector and replaced with a therapeutic gene. Recombinant AAV is capable of efficient transduction (with integration) in a number of cells in vivo. Intramuscular injection of AAV results in transduction of muscle fibers without activating destructive T cell responses even with transgenes that encode foreign proteins. [17] [18] [19] Parenteral administration of AAV will elicit neutralizing antibodies that block administration.
In this study we performed a comprehensive survey of in vitro measures of B and T cell activation to Ad5 and AAV2 in normal subjects and patients with CF.
Results
Cohorts of normal subjects (n = 45) and CF patients (n = 29) were analyzed for B and T cell responses to Ad5 and AAV2 (Table 1) . Serum was evaluated for neutralizing antibody (NAB), Ig isotypes by ELISA and specific binding to capsid proteins by Western blots. Peripheral blood mononuclear cells were evaluated for proliferation to virus (lymphoproliferative response (LPR) ) and secretion of cytokines IL-2, IFN-␥, IL-10 and IL-4. The results within the CF patients and normal controls for each of the measures are shown in Table 2 .
Immune response to adenovirus ELISA of serum showed Ig to adenovirus defined as in 71/74 (96%) individuals with IgG consistently greater than IgM or IgA (Figure 1a and b). There were no differences between normal subjects and CF patients with respect to IgM or IgA, although significantly higher levels of Ad-specific IgG were noted in normal subjects than CF (Table 2) . A wide spectrum of NAB to Ad was measured ( Figure 1c Western blot analyses were performed to evaluate the distribution of antibodies against capsid proteins. Figure  2 presents representative Western blots for 67 of 74 patients. All patients except for three had antibodies to one of the capsid proteins although the relative binding to different proteins within patients varied as follows: 37/67 (55%) had antibodies to hexon, 58/67 (87%) had antibodies to penton, and 62/67 (92%) had antibodies to fiber. A significant association was observed between NAB and antibodies to penton (P = 0.0042) with no association to hexon or fiber (Table 3 ). There were no statistically significant differences in NAB or Western profiles between normal subjects and CF (data not shown). LPR responses to Ad antigens were used to evaluate in vitro measures of activated CD4 + T cells. The validity of this in vitro correlate was tested in experiments presented in Figure 3a . Incubation of peripheral blood mononuclear cells with inactivated Ad resulted in substantial proliferation in a number of individuals, as measured by 3 H-thymidine uptake. The data are presented as the percentage inhibition of LPR. LPR responses were completely abrogated with blocking CD4 mAb. Similar inhibition of proliferation was seen in the presence of mAb to MHC class II (ie HLA-DR) but not MHC class I, consistent with the responses reflecting CD4 + T cells. Blocking antibody to CD40L (ie 5C8) and B7 (data not shown) also inhibited proliferation confirming the importance of these costimulatory pathways.
The majority of individuals (47/74, 64%) had evidence of activated CD4
+ T cells as detected by LPR stimulation index Ͼ2.0 (Figure 3b ). The specific subset of T helper cells activated to Ad was evaluated by measuring secretion of cytokines during stimulation (TH 1 cytokines (IL-2 and IFN-␥) and TH 2 cytokines (IL-4 and IL-10) ). Figure 4 shows the cytokine analysis for normal subjects and CF. There was substantial patient-to-patient variation in the secretion of each cytokine with a number of individuals not responding to antigens. IFN-␥ was secreted most consistently and at the highest levels with remarkably little IL-4 with IL-2 and IL-10 secreted at intermediate levels.
Relationships between in vitro measures of humoral and cellular immunity were evaluated using a number of statistical analyses, combining the normal subjects and CF patients ( Figure 5 and Tables 3 and 4) . A moderate but significant association (P = 0.016) exists between CD4 + T cell activation (LPR) and B cell activation as measured by NAB (Table 3) ; the patients with positive LPR responses had the positive NAB. Cytokine analysis of lymphocytes from each subject revealed frequent secretion of IFN-␥ with little IL-4 suggestive of a dominant TH 1 response ( Figure 4 ). There was a highly significant association between LPR and IL-2 and IFN-␥ secretion confirming the importance of the TH 1 phenotype (P Ͻ 0.0001, Figure  5 and Table 4 ). NAB to Ad5 was not associated with the TH 2 cytokines IL-4 and IL-10 (Table 3) .
Immune responses to AAV AAV-specific antibodies were detected by ELISA in 96% of subjects (71/74, Figure 6a and b) although only 32% showed neutralizing antibodies (24/74, Figure 6c ). No specific difference in humoral response between the two groups was noted except that AAV-specific IgM and IgA were higher in CF patients than normal subjects ( Table  2 , P Ͻ 0.0001). Western blot analysis showed antibodies to each capsid protein (ie VP-1, VP-2, and VP-3) in all serologically positive patients ( Figure 2) .
Peripheral blood mononuclear cells were analyzed for proliferation to AAV by measuring 3 H-thymidine uptake ( Figure 6d) . A minority of subjects demonstrated LPR Ͼ 2.0, (3/57, 6%); exogenous IL-2 had no effect on these in Various immunological analyses were performed on peripheral blood of CF patients and normal healthy individuals (controls). n denotes the number of samples analyzed; the mean values from all the samples in the group are presented. The comparison of each test between CF patients and normal controls were done using two-sample t tests.
Figure 1 Serum adenovirus immunoglobulins in humans. Sera from humans (a, normal; b, CF) were analyzed for the presence of adenovirus-specific IgM, IgG and IgA by ELISA as described in the Materials and methods. Each point denotes a single individual and the bar represents the mean. (c) Serial dilutions of serum were evaluated for their ability to block the infection of Hela cells by a LacZ expressing adenovirus. Antibody titers are expressed as the dilution of serum that result in a 50% reduction of Ad infection in HeLa cells without the addition of serum. This panel shows the distribution of the individuals with different NAB titers to adenovirus vector.

Figure 2 Western blot analyses to adenovirus and AAV. Sera from donors were used to probe Western blots. Adenovirus (top panel) and AAV (bottom panel) protein preparation were separated on a 10% acrylamide gel, and subjected to Western blot analyses. Serum from a rabbit immunized with adenovirus was used as a positive control for the top panel while a monoclonal antibody that detects all AAV2 capsid proteins was used as a control in the bottom panel. Positions of hexon, penton and fiber were determined by using antibodies to peptides of these proteins as controls (top panel). AAV capsid proteins were identified based on relative molecular weight (bottom panel).
vitro assays (data not shown). Supernatants from stimulated lymphocytes were largely negative for cytokines, consistent with the LPR assays (data not shown). IFN-␥ was detected in 3/57 (6%) of patients and IL-10 in 7/57 (12%) of patients; IL-2 and IL-4 were not detected (data not shown).
Discussion
The impetus for this study was the realization that host immune responses will play a significant role in the outcome of in vivo gene therapy. Experiments with adenoviral vectors clearly demonstrate the development of neutralizing antibodies that block readministration, and cellular responses that extinguish gene expression. Humoral responses are also relevant to problems of AAV readministration. Strategies to prevent these confounding responses include transient immune blockade to prevent CD4 + T cell activation and re-engineered vectors to diminish CD8
+ T cell responses. [20] [21] [22] [23] Most of this work has been performed in animal models who are naive to the virus. This will not be the case in humans, many of whom have been exposed to Ad or AAV due to a naturally acquired infection. Our survey of normal subjects and CF patients revealed interesting findings of pre-existing immunity to these viruses that are of potential relevance to the outcome of in vivo gene therapy.
Cellular immune responses to Ad were studied using lymphoproliferative responses to capsid proteins. This assay detected significant proliferation of T cells to antigen in 64% of individuals, which is lower than what was observed in a previous study where all subjects responded. 24, 25 Further study confirmed that Ad-specific responses are MHC class II restricted and mediated by CD4 + T cells, findings consistent with previous studies using wild-type Ad antigens. We further showed the requirement of CD40L-CD40 and B7-CD28 interactions in CD4
+ T cell activation. Different levels of responsiveness to Ad could reflect variations in prior exposure to a naturally acquired infection or HLA heterogeneity.
The qualitative nature of T cell responses in terms of T helper subsets was evaluated by measuring secreted cytokines in response to Ad. IFN-␥ and IL-2 were used as markers of a TH 1 response while IL-10 and IL-4 Associations for various parameters (column 1) with positive or negative neutralizing antibodies to adenovirus (defined as Ͻ20). P values for association between NAB and other measures are based on a 2 text on one degree of freedom.
Figure 3 Characterization of adenovirus-vector-mediated LPR responses in normal and CF individuals. (a) Peripheral blood lymphocytes from five individuals from a separate cohort, who responded to adenovirus antigens, were cultured with inactivated Ad vector (1 × 10 9 particles/ml) in the presence of various concentrations of antibodies directed to HLA-DR (anti-HLA-DR mAb), CD4 (OKT4A mAb), CD40L (5C8), or MHC class I (W6-32 mAb). Lymphoproliferation was measured by 3 H-thymidine incorporation and presented as stimulation index of c.p.m. from adenovirus stimulated cultures per c.p.m. in the presence of medium alone. A stimulation index of Ͼ2.0 was considered positive. The y-axis shows percent inhibition of LPR responses by the antibodies, compared with control responses in the absence of any antibody. Each point denotes mean and s.d. of five separate donors. (b) LPR measurements from normal subjects and CF (P = 0.32, two-tailed t test).
reflected TH 2 response. We did this with the disclaimer that the TH 1 /TH 2 dichotomy developed in mice may not precisely reflect the situation in humans. 26 Our cohort of subjects did show a significant association between LPR responses and secretion of IL-2 and IFN-␥. Induction of IL-4 was observed only in some individuals; no significant correlation was observed with LPR responses. This was surprising in light of the more extensive prevalence of memory B cells as suggested by NAB in 55% of patients. It is possible that other cytokines or T helper subsets contribute to B cell activation in this system. Alternatively, this may reflect limitations of the IL-4 ELISA.
No clear associations of humoral and cellular immunity were noted with Ad-stimulated secretion of IL-10. We focused specifically on any relationship with LPR because of recent work, which implicated IL-10 on inhibition of T cell functional responses. 27 IL-10 was found across a spectrum of LPRs from stimulation index of 1 to 100. Further analysis of non-responding IL-10-secreting cells indicated they express IFN-␥ but not IL-2. Such cells have been recently classified as TH 3 cells, which play a role in regulation of immune reactivity to tolerant antigens in infectious agents. 28, 29 Antibodies reactive to Ad capsid proteins were present in 97% of individuals based on Western and ELISA
Figure 4 Cytokine secretion patterns induced by adenovirus. Peripheral blood lymphocytes were cultured in the presence or absence of inactivated Ad for 48 h and culture supernatants assayed for the presence of cytokines (IFN-␥ (a), IL-2 (b), IL-4 (c) and IL-10 (d) ) by commercial ELISA kits. Each point denotes a single individual. The data are presented for both normal subjects and CF as concentration of cytokine (pg/ml).
assays. These were primarily IgG, which recognized penton, hexon and fiber at variable levels. Interestingly, serum from only 55% of subjects actually neutralized Ad infection in vitro. Why the discrepancy between seropositivity, based on Western and ELISA, and neutralization of virus? Each individual likely has a different history of infections with more than one of the over 40 Ad serotypes. The circulating antibodies resulting from these memory B cell responses will bind with varying efficiencies to Ad serotypes within and between adenovirus groups. The Western and ELISA assays are probably more sensitive in detecting antibodies across all serotypes, while the neutralizing assay is more stringent in terms of serospecific responses. An important question is which in vitro assay will predict interference of gene transfer in vivo? In this respect, a recent study has demonstrated that pre-existing humoral immune responses did not preclude gene transfer. 30 Our strategy to date in human trials is to include all patients in trials, irrespective of in vitro measures of pre-existing immunity, and to develop correlations between the in vitro assays and efficiency of in vivo gene therapy.
Profiles of immune activation to AAV were quite different than what was observed to Ad. ELISA and Western did detect antibodies in 96% of individuals, with only 32% capable of neutralizing an in vitro AAV infection.
The high prevalence of seropositivity to AAV is consistent with previous epidemiologic studies. 1 The three subjects who had no evidence of immunity to Ad were also negative for AAV responses confirming the symbiotic relationship of these viruses in humans. Interestingly, only 5% of subjects showed proliferative responses to AAV antigens. It is unclear why the substantial discordance between CD4 + T cell responses and memory B cell activity. It is possible that a component of AAV humoral response is T cell-independent.
The implications of our studies on AAV immunity in humans is unclear. Some humans clearly have significant levels of neutralizing antibody to AAV2 which could impact on the efficiency of in vivo gene engraftment. Prevalence of NAB to AAV2 is lower than NAB to Ad5, however. The nature of the B cell response to AAV2 needs clarification to help design strategies to prevent it from occurring in therapies that require readministration of vector.
Materials and methods
Human subjects
Normal volunteers (n = 45), and CF patients (n = 29) were analyzed for immune reactivity to adenovirus and AAV. Some assays were not done in all the samples due to low cell numbers, lack of samples, or invalid assay conditions. The numbers of individuals tested for each assay are specified in Table 2 . Individuals were derived from the local CF clinic and members of the University of Pennsylvania community. The study was approved by the Institutional Review Board. Demographics of the individuals in the study are shown in Table 1 . The median age was 27 years (range 18 to 54 years) and the age distribution was similar in the two groups. An additional 10 individuals were analyzed for adenovirus-specific lymphoproliferative responses. All these samples were pretreated with either medium alone, or various antibodies. Five of 10 individuals responded strongly in this assay, and were used for the data in Figure 3a .
Recombinant viruses
The structure, production, and measurement of titer of E1-deleted recombinant adenovirus virus based on serotype 5 (H5.010CMVlacZ, hence called Ad-lacZ) that express ␤-galactosidase (CMV promoter in sub360 backbone) have been described previously. Recombinant adeno-associated virus (AAV2lacZ, hence called AAV), deleted of rep and cap genes was generated by plasmid transfections in 293 cells infected with E1-deleted adenovirus as described earlier.
Lymphoproliferative assays
Peripheral blood mononuclear cells (PBMC) were harvested from 40 ml of heparinized blood and isolated following Ficoll-Hypaque density gradient centrifugation, washed in PBS and resuspended in RPMI 1640 and supplemented with 10% FCS, penicillin, streptomycin, and 10 −5 m 2-mercaptoethanol. Triplicate cultures PBMC (100 l of 1 × 10 6 cells/ml) were cultured with either inactivated Ad-lacZ (MOI in particles = 10) or rAAV (MOI in particles = 100) supplemented with 0.5 g/ml phytohemagglutinin (PHA, Difco, Detroit, MI, USA) or medium alone. PHA-stimulated cultures were harvested on day 3 and antigen-stimulated cultures were harvested on day 6. In some cases, exogenous recombinant IL-2 (Immunotech IC, Westbrook, ME, USA) or antibodies to CD4 (Leu3a mAb); HLADR, MHC class I (HLA-A,B-C, Becton Dickinson, Mountain View, CA, USA), CD40L (5C8, Biogen, Boston, MA, USA), or B7-1 (Pharmingen, San Diego, CA, USA) were added to the cultures. Proliferation was measured by a 16-h Cytokine release assays PBMC were cultured with or without antigen (ie inactivated Ad or AAV) for 48 h in a 24-well plate. Cell free supernatants were collected and analyzed for presence of IL-2, IL-4, IFN␥ and IL-10 by commercial ELISA kits (BioSource, Rahway, NJ, USA) using manufacturer's protocols.
Vector-specific immunoglobulins Serum (diluted 1:200) samples from donors were analyzed for Ad-and AAV-specific isotype specific immunoglobulins (IgM, IgG, IgA) by ELISA. For the ELISA, 96-well flat bottomed, high-binding ELISA plates (Costar, Cambridge, MA, USA) were coated with 100 l Ad-antigen (5 × 10 9 particles/ml) or AAV (1 × 10 9 particles/ml) in PBS overnight at 4°C, washed four times in PBS/0.05% Tween and blocked in PBS/1% BSA for 1 h at 37°C. Appropriately diluted samples were added to antigencoated plates and incubated for 4 h at 37°C. Plates were washed four times in PBS/0.05% Tween and incubated with peroxidase conjugated goat anti-human IgM, IgG or IgA (1:2000 dilution, Sigma Chemical, St Louis, MO, USA) for 2 h at 37°C. Plates were washed as above and ABST substrate (Kirkegaard and Perry, Gaithersburg, MD, USA) was added. Optical densities were read at 405 nm on a MRX microplate reader (Dynatech Laboratories, Chantilly, VA, USA).
Western blot analyses Serum samples were analyzed for reactivity to various Ad proteins by Western blot as described earlier. Whole virus particles were boiled in sample buffer and used as a source of adenovirus antigens from Ad and AAV. A polyclonal rabbit antiserum (for Ad) and monoclonal antibody that recognizes shared epitopes on VP1, VP2, VP3 (clone B1, American Research Products, Piscataway, NJ, USA) as a positive control. The antibodies to hexon, penton and fiber were identified by probing the nitrocellulose blots with polyclonal antibodies generated against hexon, penton and fiber specific peptides. Briefly, Ad antigens were electrophoresed on a 10% SDS-PAGE and transferred to nitrocellulose membrane (Hybond-ECL, Amersham, Pistcataway, NJ, USA). The reactivity of the serum was measured by incubating test serum, followed by peroxidase anti-human IgG antibody. The reaction was detected by the ECL chemiluminiscence kit (Amersham).
Anti-adenovirus and AAV neutralizing antibodies
Neutralizing antibody titers were analyzed by assessing the ability of serum antibody to inhibit transduction of reporter virus, Ad-lacZ, or AAVlacZ into Hela or 84-31 cells, respectively. The 84-31 line is a subclone of 293 cells that stably expresses E4 of Ad that renders it permissive for AAV transduction. Various dilutions of antibodies pre-incubated with reporter virus for 1 h at 37°C, were added to 90% confluent cell cultures. Cells were incubated for 16 h and expression of lacZ, was measured by staining with X-gal substrate. The neutralizing titer of antibody was calculated by the highest dilution with which 50% of the cells stained blue.
Statistical methods
Continuous measures were compared between groups using two-sample t tests. Chi-square tests were used to evaluate measures of association between dichotomous outcomes. Pearson correlation coefficients were used to evaluate linear relationships among continuous outcome variables. For some analyses and outcomes, measures were further analyzed by first dichotomizing into 'negatives' and 'positives' according to standard cut-offs. The cut-off values used for these outcomes were immunoglobulins 0.050; LPR stimulation index 2.0; cytokines 0.0; neutralizing antibodies 20. Analyses utilized the S-Plus and StatXact statistical analyses packages.
